The Impact Of Clinical Pharmacists Medication Reconciliation Upon Patients Admission To Reduce Medication Discrepancies.

October 9, 2022 updated by: Heba Shaker, Alexandria University

A Comparative Prospective Interventional Study Shows The Impact Of The Clinical Pharmacists' Role In The Emergency Department In Medication Reconciliation Upon Patients' Admission To Reduce The Medication Discrepancies.

It is a quazai one arm study shows the impact of the role of the clinical pharmacists through medication reconciliation to patients admitted to the emergency department .The main aim is to show if the pharmacists intervention is associated with establishing a complete drug history list than the list already presented in the patient file and taken by the physician .Then a description of the medication errors detected will be done .

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

It is a quazai one arm study in which the pre phase is the detection of the complete and accurate drug history list already presented in the patient file and taken by the physician and the post phase is the detection of the complete and accurate drug history list taken by the clinical pharmacists after medication reconciliation for the same patients.

medication reconciliation will be done as a full diseases and preadmission medications history will be taken from the patients or the family through interviews, revising previous prescriptions and hospital records.

  • Preadmission medication history will include medications trade names, doses, frequency and route of administration and treatment duration and also will include the consumption of vitamins or herbs.
  • The medication errors will be detected ,calculated and classified according to medication at transitions and clinical handoffs (MATCH) toolkit for medication reconciliation and NCC MERP index.

Study Type

Interventional

Enrollment (Actual)

161

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Alexandria, Egypt
        • Alexandria Main University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with one or more chronic disease / drug.

Exclusion Criteria:

- Patients who cannot communicate or have no family members.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: HEALTH_SERVICES_RESEARCH
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: patients admitted to emergency department
the intervention is the medication reconciliation
Other: medication reconciliation
the emergency clinical pharmacists will start medication reconciliation with the admitted patients and a full diseases and preadmission medications history will be taken.A comparison between the accuracy and completeness of drug history lists already presented in the profile and drug history taken by the clinical pharmacists to detect the medication discrepancies

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the total number of complete and accurate drug history list detected in each phase.
Time Frame: 2 months
to calculate the total number of complete and accurate drug history list taken by the physicians and already presented in the profile (pre phase) and the total number of complete and accurate drug history list taken by the clinical pharmacists after medication reconciliation (post phase).
2 months
Detect the number of medication discrepancies and the proportion of the prescriptions with one or more medication discrepancies
Time Frame: 2 months

Calculate the total number of medication discrepancies detected after medication reconciliation and then calculate and the proportion of the prescriptions with one or more medication discrepancies from the total number of prescriptions.

2- to classify the medication discrepancies using Medications at Transitions and Clinical Handoffs (MATCH) Toolkit for Medication Reconciliation.

2- to classify the medication discrepancies using Medications at Transitions and Clinical Handoffs (MATCH) Toolkit for Medication Reconciliation.

2- to classify the medication discrepancies using Medications at Transitions and Clinical Handoffs (MATCH) Toolkit for Medication Reconciliation.

to classify the medication discrepancies using Medications at Transitions and Clinical Handoffs (MATCH) Toolkit for Medication Reconciliation and NCC MERP index
2 months
classification of medication discrepancies
Time Frame: 2 months

to classify the medication discrepancies according to MATCH toolkit for medication reconciliation and NCC MERP index.

3- to calculate the proportion of the patients detected with one or more medication discrepancies

3- to calculate the proportion of the patients detected with one or more medication discrepancies

3- to calculate the proportion of the patients detected with one or more medication discrepancies to calculate the proportion of the patients detected with one or more medication discrepancies
2 months
the total number of complete medication history lists will be written in the patients profiles
Time Frame: 2 months
to calculate the total number of complete medication history lists will be written in the patients profiles by the clinical pharmacists after their interventions..
2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Alexandria University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 25, 2020

Primary Completion (ACTUAL)

November 30, 2020

Study Completion (ACTUAL)

November 30, 2020

Study Registration Dates

First Submitted

May 16, 2020

First Submitted That Met QC Criteria

May 16, 2020

First Posted (ACTUAL)

May 20, 2020

Study Record Updates

Last Update Posted (ACTUAL)

October 13, 2022

Last Update Submitted That Met QC Criteria

October 9, 2022

Last Verified

December 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 0304494

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Medication Reconcilitation Upon Hospital Admission

Clinical Trials on medication reconciliation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe